Introduction {#S1}
============

Human immunodeficiency virus 1 (HIV-1) is a highly pathogenic retrovirus that causes immune system degeneration ([@B1]). In the past 30 years, antiretroviral therapy has achieved considerable advances. However, despite remarkable scientific achievements in HIV-1 diagnosis and treatment, acquired immune deficiency syndrome (AIDS) still prevails and there are estimated 35 million people worldwide living with HIV-1 infection or AIDS ([@B2], [@B3]). The innate immune system, a significant alarm system in our body, has been caught more attention on resisting foreigner pathogens in recent years ([@B4]--[@B6]). One of the key effector molecules in innate system is interferons (IFNs), which rapidly respond to virus infection by a broadly, non-specific manner.

Interferons are classified into three groups based on the structure of their receptors: type I (IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ), type II (IFN-γ), type III (IFN-λ1, IFN-λ2, and IFN-λ3). Among these three types, IFN-I bind to a cell surface receptor complex known as the IFN-α/β receptor (IFNAR), which consists of IFNAR1 and IFNAR2 chains ([@B7]). Contrary to the limited expression of type II and type III interferons receptor, IFNAR is widely expressed on almost all kinds of immunocytes and epithelial tissue ([@B5], [@B8], [@B9]), suggesting that IFN-I have an extensive influence and are able to arouse quick activation of the whole immune system.

Innate immune responses mainly derive from the recognition of viral pathogen-associated molecular patterns (PAMPs) by host pattern recognition receptors (PPRs) such as toll-like receptors (TLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), and other DNA-sensing receptors ([@B10]--[@B12]). Upon sensing PAMPs, several downstream signal molecules and transcriptional factors will be recruited, subsequently production of IFNs, especially IFN-I, is stimulated. At the earliest stage of acute infection, the production of IFN-I and other inflammatory cytokines is an essential event to determine the rate of virus replication and spreads ([@B11], [@B13], [@B14]). Unfortunately, this response is usually ineffective to suppress HIV-1 activity, due to the ability of this virus to hijack host immune system and evade the IFN-mediated antiviral activities ([@B4]). Moreover, the persistent IFN-I secretion greatly disturbs the immune homeostasis, contributing to immune activation-dependent disease progression ([@B15], [@B16]).

The administration of IFN-I, especially IFN-α, as monotherapy or an adjunct to combined antiretroviral therapy (cART), has been intensively reported ([@B17]), but the results varied greatly. In addition, as the continuous IFN-I production impedes immune recovery and enhances T cells exhaustion, IFN-I blockade may provide another strategy to weaken the virus-induced immune hyperactivation in the chronic HIV-1 infection ([@B18], [@B19]). Actually, inhibition of IFN-I system is likely to be an efficient way to reverse excessively elevated IFN-I signaling and rescue specific anti-HIV-1 immunity ([@B20]). Concerning the extensive impact of IFN-I system, it is unclear whether this method to shut off the IFN-I system is beneficial to pathogenesis or merely a secondary effect.

In this review, we will discuss the stimulation of IFN-I by sensing viral pathogens after HIV-1 infection, the antiviral/immunomodulatory activities of IFN-I on different immunocytes, and the manipulation of IFN-I system as a therapeutic strategy *in vivo*.

The Induction of IFN-I in the Process of HIV-1 Infection {#S2}
========================================================

Recognition of HIV-1 by PRRs in Innate Immune System {#S2-1}
----------------------------------------------------

At the beginning of infection, HIV infects immunocytes such as dendritic cells, macrophages and CD4^+^ T cells in the human intestinal mucosal. In this process, virus can be rapidly recognized by innate immune system through a series of complex mechanisms as follows. The initial sensing of HIV-1 is mediated by PRRs. There are four classes of PRRs family have been identified, including transmembrane protein as TLRs and C-type lectin receptors, as well as cytoplasmic proteins as RLRs and NOD-like receptors ([@B21]). They recognize conserved structures of HIV-1 nucleic acid, which is called PAMP. The interaction between PAMP and PRRs will result in different level of immunocytes activation. And evidence has been found that plasmacytoid dendritic cells (pDCs) produce the highest level of IFN-I once sensing PAMP, whereas the production of IFN-I is barely detectable in other immune cells ([@B22]).

HIV *in vivo* can be divided into two types: cell free virus and cell-associated virus. The former is the virus infected directly from outside; while the latter is produced through viral RNA reverse transcription, integration and packaging in infected CD4^+^ T cells (Figure [1](#F1){ref-type="fig"}). However, they enter pDCs through separate pathways. Cell free virus are taken up by pDCs through endocytosis mediated by envelope--CD4 interaction ([@B23], [@B24]), while cell-associated virus enter pDCs by fusion or endocytosis ([@B14]). Although cell-associated viruses are at a high level *in vivo*, they are a less potent inducer of IFN-I than cell free virus ([@B25]). One of the possible reasons is that most of cell-associated viruses are defective viruses which are not able to induce effective immune responses.

![Recognition of human immunodeficiency virus 1 (HIV-1) by innate immune system. In plasmacytoid dendritic cells (pDCs), cell-free HIV is taken up through endocytosis while cell-associated virus enters into pDCs by fusion and endocytosis. The single-strand RNA (ssRNA) released from virus is recognized by TLR3 and TLR7. Then the activated toll-like receptors (TLRs) stimulate MyD88 and TRIF signal pathway, recruit NF-κB and interferon-regulatory factor (IRF)-7, respectively, to trigger type-I interferons (IFN-I) production. In macrophages and CD4^+^ T cells, HIV-1 enters cells mainly through fusion and endocytosis. But the ssRNA is detected by retinoic acid-inducible gene (RIG)-I, which stimulates mitochondrial antiviral signaling protein (MAVS)--IRF-3 dependent pathway, and next moderately induces the expression of IFN-I.](fimmu-08-01431-g001){#F1}

Plasmacytoid dendritic cells highly express TLR7, which greatly enhances their ability to produce IFN-I up to 1,000-fold more than other cell types' response to HIV-1 infection ([@B26]). In the cytosol of pDCs, HIV nucleic acid is presented to TLR7 located in endosomes, which is transferred from the endoplasmic reticulum (ER) to endosome *via* polytopic membrane protein UNC93B1 and heat shock protein gp96 ([@B27], [@B28]). After the formation of endosomes, TLR7 rapidly catches up with single-strand RNA (ssRNA) ([@B29]). But the specific character of these ssRNA has not been identified. Moreover, TLR3 is the other essential TLR expressed in pDCs, which detects both ssRNA and double strands RNA (dsRNA) ([@B30], [@B31]). Similarly, TLR3 also transferred from ER to endosome. In mature endosome, activated TLR7 and TLR3 by pathogenic nucleic acid is phosphorylated by tyrosine kinase-Src ([@B32], [@B33]). Although TLR7 and TLR3 are both explicitly expressed in pDCs, TLR7 plays a more important role in recognition of pathogenic nucleic acid and stimulation of IFN-I in response to HIV-1 infection ([@B34]).

Although ways of HIV-1 entering into macrophage and CD4^+^ T cells are similar to that entering into pDCs, the recognition of HIV nucleic acid by these cells are completely different. In these cells, viral RNA is detected by RIG-I, a cytosolic receptor, without the generation of endosomes. RIG-I is a member of DExD/H box RNA helicases family. The crystal structure of RIG-I can be divided into three distinct domains: N-terminal region consisting of caspase activation and recruitment domains (CARD) to trigger IFN-I secretion; a central DExD/H box RNA helicase domain binding to specific RNA; as well as C-terminal repressor domain ([@B35], [@B36]). Just because of the special structure of RIG-I, PAMP of RNA virus whose sequence is marked with 5′ triphosphorylated (5′ppp) ends could be well recognized ([@B35]). It is by 5′ppp marks that RIG-I distinguishes exogenous RNA from their own ([@B37]). Various studies confirm that RIG-I^−/−^ mice become more susceptible to RNA virus infection ([@B35], [@B38], [@B39]). Furthermore, stimulating the RIG-I pathway by retinoic acid effectively reactivates HIV reservoirs and promotes apoptosis of these infected cells, leading to the enhancement of innate immune system to eliminate latent reservoirs ([@B40]).

Interferon-Regulatory Factors (IRFs) Regulating the Production of IFN-I {#S2-2}
-----------------------------------------------------------------------

Interferon-regulatory factors are a member of transcription factors that place in the central position of innate immune responses. Actually, they play a crucial role in bridging PRRs and the induction of IFN-I in gene-regulatory network ([@B4]). IRFs family consist nine members: IRF 1--9. The common of these transcriptional factors is that they all contain a conserved DNA-binding domain to recognize DNA sequences known as IFN-stimulated response element ([@B41]). Especially IRF-3 and IRF-7, they are main regulators in producing IFN-I among pDCs, macrophages and CD4^+^ T cells after the interaction of PAMP and PPRs.

Interferon-regulatory factor-7 has attracted much attention for its function in pDCs. Upon recognition of HIV-1 ssRNA by TLR7 and TLR3 in endosome, a complex including IRF-7, IRAK, TRAF6, and other proteins are rapidly recruited ([@B42], [@B43]). However, the complex is engaged by these two TLR through distinct pathways: TLR7 is mediated by a MyD88-dependent manner whereas TLR3 by TRIF ([@B44], [@B45]). The establishment of complex drives the phosphorylation of IRF-7 by IRAK1 and IKKα. Then phosphorylated IRF-7 translocates from cytoplasm into nucleus, attach to the promoter of IFN-I and increase their expression ([@B42], [@B46]). At the same time, the complex activates NF-κB by a MyD88-TRAF6 dependent pathway, which further stimulates the production of IFN-1. Notably, phosphorylated IRF-7 can form a dimer (a homodimer or a heterodimer with IRF-7), which stimulates the activity of histone-acetyltransferase to loosen chromatin structure and facilitate more efficient transcription of IFN-I ([@B47]).

The other significant IRFs that have been intensively studied in HIV infection is IRF-3. Similar to IRF-7, IRF-3 also resides in the cytosol. However, the recruitment of IRF-3 follows the interaction between viral RNA and RIG-I in macrophage and CD4^+^ T cells ([@B37]). During viral infection, 5′ppp RNA PAMPs bind to R-terminal region of RIG-I, which cause the release of CARD to trigger CARD-depended interaction with mitochondrial antiviral signaling protein (MAVS) that is located on the outer mitochondrial membrane ([@B48], [@B49]). The activation of MAVS strongly catalyzes 2,3′-guanosine-adenosine monophosphate (cGAMP), which is the paramount agonist of stimulator of interferon genes (STING). STING initially aggregate around the MAVS, then stimulate the downstream signaling cascades that involve multiple kinases and finally lead to the phosphorylation of IRF-3 ([@B50]). Following behind phosphorylation, IRF-3 shares the similar mechanism of facilitating the transcription of IFN-I as IRF-7. Importantly, recent advances show that reverse transcribed HIV-DNA but not its RNA induces IRF-3 activation and IFN-I production depend on cGAMP--STING--IFI16 pathway in macrophage ([@B51]--[@B53]). In addition, the polyglutamine binding protein 1 (PQBP1) is recently identified as the co-receptor of HIV-DNA to trigger cell-autonomous antiviral responses ([@B54]). Therefore, PQBP1 as an immune regulator provides a pharmacological target to improve the efficiencies of HIV medicine. However, sensing of HIV-DNA by IFI16 cannot induce IFN-I production in CD4^+^ T cells, resulting the HIV evasion from innate immune system and formation of HIV reservoirs ([@B55]).

Interestingly, IRF-3 functions at the initial transcription of IFN-I gene. Whereas IRF-7, the upregulation of which also need the stimulation by IFN-I itself, is involved in the late phase of IFN-I gene induction. That is to say, the induction of IFN-I by IRF-3 is mediated by a two-step activation, which forms a positive-feedback-loop ([@B56]). It is likely another reason that pDCs produce the highest level of IFN-I as is mentioned earlier.

Effects of IFN-I on Immunocytes in Chronic HIV-1 Infection {#S3}
==========================================================

Unlike the effective response in other infectious diseases, IFN-I in HIV-1 infection becomes rapidly dysfunctional and unable to purge the virus finally. Inversely, as the widely expression of IFNAR, prolonged virus replication and sustained stimulation of IFN-I progressively induce a generalized immune activation, injured inflammation, as well as T cell exhaustion ([@B2], [@B46]). Moreover, a strong correlation between the levels of IFN-I and disease progression has already been observed. In the models of simian immunodeficiency virus (SIV) infection, the common character of long time non-progression macaques is that they can induce rapid and transient high levels of IFN-I but declines in the chronic phase ([@B19], [@B57], [@B58]). Though the administration of cART can effectively suppress the replication of HIV-1, it cannot completely reverse the immune hyperactivation caused by IFN-I ([@B59], [@B60]). In the lymphocytic choriomeningitis virus (LCMV) mouse models, persistent production of IFN-I exacerbates CD4^+^ T cell exhaustion and is detrimental to its antiviral response ([@B61]--[@B63]). Other researches also indicate that chronic infection of LCMV induces inhibitory molecules expression and apoptosis of Treg ([@B64], [@B65]). These studies suggest that compare to a positive role of IFN-I on restricting virus spread and replication at the acute phase of infection, IFN-I tend to exert a negative effect on different immunocytes in chronic HIV-1 infection.

Plasmacytoid dendritic cells are a special dendritic cell subset that produces a large amount of IFN-I in the process of HIV-1 infection. With the progression of HIV-1 infection, pDCs gradually decrease in blood while accumulate in lymph nodes. pDCs from these lymph nodes secrete higher titer of IFN-α spontaneously but not express co-stimulatory molecular ([@B66]). These nonfunctional cells are continuously produce IFN-I but cannot develop into mature antigen presentation cells. Instead, the redistributed pDCs increase staining of Annexin V and thus exhibit apoptosis ([@B67]). Even for cART treatment patients, the frequency and function of pDCs in peripheral blood is decline and accumulate in gut-associated lymphatic tissue ([@B68]). Moreover, in the chronic phase of HIV-1 infection, the excessive IFN-I may result in the dysregulated activation and even depletion in pDCs. In SIV models, a negative correlation between the decline of circulating pDCs and overexpression of IFN-I are observed during pathogenic SIV infection of macaques, but not in natural ones ([@B69]). Furthermore, pDCs with the upregulation of β7-integrin and CD103 are aggregated to the colorectum in chronic HIV-1 infected patients, which facilitates much more production of IFN-I ([@B70], [@B71]). Unfortunately, the amount of IFN-I produced by these lymphatic tissues is much more than what organisms really need to fight infection ([@B71]). Furthermore, these redundant IFN-I will lead to the activation of innate immune system and conversely damage the normal function of pDCs. However, the specific mechanism how IFN-I interacts with pDCs has not been clearly elucidated. There are two possible reasons for this phenomenon: On the one hand, pDCs that are persistently stimulated by IFN-I express low levels of migration receptors and regulatory factors, such as CCR7, CD40, and CD86. These pDCs produce IFN-I since pathogenic nucleic acid traffics to the endosome ([@B72], [@B73]), which induces apoptosis to these out-of-control cells mediated by the TNF-related apoptosis-inducing ligand (TRAIL) ([@B74]). On the other hand, IFN-I activates the non-canonical NF-κB signaling in pDCs. This pathway will promote the expression of indoleamine 2,3-dioxygenase, the most essential factor to gather regulatory T cells (Treg) ([@B75]). These pDCs-induced Treg intensively inhibit the maturation of pDCs through the engagement of cytotoxic T-lymphocyte antigen (CTLA)-4 and PD-1 on these activated pDCs ([@B6]).

Natural killer (NK) cells play a crucial role in innate immune system that act as the first line to defense HIV-1. First, the interaction between killer immunoglobulin-like receptors expressed on the surface of NK cells with their cognate HLA ligands sets a guarantee recognize specific HIV-derived peptides and eliminate HIV-1 infected cells ([@B76], [@B77]). Second, antibody-dependent cellular cytotoxicity (ADCC) is the other way of NK cells to control HIV-1 infection. Notably, ADCC activity was associated with the modest protective efficacy in the RV144 HIV vaccine trial ([@B78]). Moreover, new data show that the levels of NK cells activation is tightly associated with HIV-1 virological suppression in patients receiving cART ([@B79]). Patients who initiate ART early during infection obtain the improvement of cytotoxic function of the NK cells while decline of the levels of ADCC mediating antibodies ([@B80], [@B81]). These data suggest that NK cells. However, during the whole phase of HIV-1 infection, the relation between NK cells and IFN-I is complicated. In the acute infection, IFN-I has been observed to promote NK cells survival, expansion, maturation, activation and enhance their cytotoxic activity against virus ([@B82], [@B83]). In IFNAR^−/−^ mice, there are barely detectable mature NK cells in peripheral blood ([@B84]). Identically, impaired cytotoxicity ability as well as a loss of highly activated subset of NK cells has been found in rapid progressors ([@B85]). But in the chronic HIV-1 infection, IFN-I may greatly disturb the normal function of NK cells. First, despite viral control well, NK cells are consistently activated in the chronic HIV-1 infection after the establishment of reservoirs. In the presence of high level of IFN-I, activated NK cells attenuate the cytotoxicity of CD8^+^ T cells response to virus infection. As the suppressed function of NK cells and CD8^+^ T cells, HIV escape from ADCC and CTL effect ([@B86]). Another research demonstrates that NK cells-depletion mice promoted virus-specific T cells response and contributed to viral control ([@B87]). Second, IFN-I disturbs the balance between STAT1 and STAT4, two downstream transcriptional factors of IFNAR in NK cells. In HCV/HIV coinfected patients, high level of IFN-I is relevant to the upregulation of STAT1 while downregulation of STAT4, which increase the expression of perforin induced by interleukin (IL)-12 ([@B88]). This mechanism further prompts the nonfunctional activation of NK cells. Thirdly, IFN-I decreases the production of IFN-γ through upregulating the expression of IL-10 and PD-L1 in NK cells ([@B89]), which further weaken their cytotoxic effects.

It is well established that HIV-infected patients maintain persistently high circulating CD8^+^ T cells number, in spit of many years of therapy ([@B90]). The CD4/CD8 ratio often fails to become normal despite CD4 count normalization. Notably, new data showed that the majority of CD8^+^ T proliferation and activation was induced in an antigen-independent manner ([@B91]). The great disturbing of T cell homeostasis makes the immune system dysfunctional and exhausted in the chronic HIV-1 infection. It is intensely investigated that IFN-I is responsible for the expansion of CD8^+^ T cells. On the one hand, IFN-I has been shown to induce memory CD8^+^ T cells proliferation and differentiation through bystander effect ([@B92], [@B93]). Thus, it is hypothesis that sustained exposure to IFN-I could contribute to CD8^+^ T cell persistence. On the other hand, during the chronic infection, IFN-I favor the formation of terminally differentiated CD8^+^ T cells that do not renew but enhanced cytotoxic function. This subset skewing likely contributes to the progressive IFN-I-mediated immune dysregulation ([@B61], [@B89]).

As we all known, HIV-1 features as the destroyer of CD4^+^ T cells. It is the death of this kind of cell that propels the late phase of clinical procession, AIDS ([@B2], [@B26]). Although IFN-I could silence T cells to limit viral replication and program cells death to get rid of HIV-1 infection, IFN-I also influence the differentiation of T cells and induce death of HIV-1 uninfected cells *via* bystander effect ([@B92], [@B94]). On the one hand, depending on cytokine environment, naïve CD4^+^ T cells mainly differentiate into Th1, Th2, Treg, and follicular T helper (Tfh) cell populations that have different biological functions ([@B95]). Actually, continuously stimulated by IFN-I facilitate naïve CD4^+^ T cells differentiate toward Th2 cells, leading to a severe disproportionality of Th1 and Th2 ([@B96], [@B97]). On the other hand, IFN-I induces apoptosis of uninfected CD4^+^ T cells in peripheral blood and in secondary lymphatic tissue by upregulating TRAIL expression on CD4^+^ T cells, leading to the destruction of lymph node in gastrointestine in the acute phase of HIV-1 infection ([@B98]). Recent studies revealed that the death of 95% resting, non-permissive CD4^+^ T cells are caused by caspase-1-mediated pyroptosis, a highly inflammatory form of programmed cell death ([@B99], [@B100]). With the stimulation of IFN-I, the expression of PD-1 is upregulated in exhausted T cell. Instead, blockade of PD-1/PD-L1 pathway helps to restore the function of T cells and decrease the viral load ([@B101]). Another studies also show that IFN-I significantly suppress HIV-1-specific CD4^+^ T response, while blockade of IFN-I signaling pathway inactivates immune system, downregulates the expression of negative immune-regulatory factors and maintains the lymphoid structure after chronic LCMV infection ([@B89], [@B102]). In the model of humanized mice, blocking IFNAR rapidly enhances CD4^+^ T recovery and reduces HIV-1 reservoirs ([@B103]).

Recently, a special subset of CD4^+^ T cells, Tfh cells, has been intensively reported for its function to induce memory B cells activation, survival, differentiation, as well as assist B cells to produce antigen-specific neutralizing antibodies. At the same time, Tfh cells act as the major CD4^+^ T cells compartment for HIV-1 infection, replication, and long-lived viral reservoirs ([@B104], [@B105]). In the chronic HIV-1 infection, the differentiation of Tfh cells impairs greatly as the repressive effect by excessive production of IFN-I and the activation of signal transducer and activator of transcription 3 ([@B106]). But this effect can be partly conversed by blocking the IFNAR in mice ([@B107]). Moreover, the population of HIV-specific Tfh cells expand during the chronic phase in patients who have a relatively high level of plasma HIV-RNA and IFN-I, which in turn leads to perturbation of B-cell differentiation, resulting in dysregulation antibody production ([@B108]). While in elite controllers, a stronger capacity to induce B cells maturation in Tfh cells is always tightly correlated to the low level of IFN-I ([@B109], [@B110]).

In addition, several studies indicate that the IFN-I also damage the normal function of B cells in the consistent presence of IFN-I. Indeed, IFN-I, especially IFN-α, is one of the most essential factor that contribute to the B-cell hyperactivation and exhaustion in HIV-1 viremic individuals ([@B111]--[@B113]). The loss of CD21 expression on exhausted B lymphocytes is a reliable marker of HIV-1 disease progression ([@B114]). It has been demonstrated that these cells that express low levels of CD21 is associated with the high expression of inhibitory markers as PD-1 and CTLA-4 ([@B115], [@B116]). Interestingly, IFNAR also express highly in these cells, which suggests that IFN-I plays a role on B cells dysfunction ([@B117], [@B118]). Another subpopulation of lymphocytes response to IFN-I is Treg, who work as a dominant role in immunosuppressive function to protect body from unwanted immune responses and maintain the homeostasis of immune system ([@B119]). However, the function of Treg is suppressed during the process of HIV-1 infection. When IFN persistently stimulated by IFNAR expressed on Treg, downstream signaling molecules will have impact on the expansion and suppressed function of Treg in turn ([@B120]). On the one hand, IFN-I inhibits Treg proliferation through a higher phosphorylation of STAT1 and a lower expression of suppressor of cytokine signaling 1 ([@B121]). Notably, this inhibition is tightly correlated with lower frequency of virus-specific CD8^+^ T response and viral clearance ([@B122]). On the other hand, chronic HIV-1 infection also leads to the downregulation of Foxp3. Foxp3 appears to act as a master regulator on the development and suppression function of Treg ([@B123], [@B124]). The possible mechanism is that IFN-I induces the secretion of IL-10 and decreases transforming growth factor-β. The overexpression of inhibitory inflammatory factors will competitively inhibit the suppressive function of Treg to rectify the disorder in immune system, which causes dysregulation in Foxp3 ([@B125]--[@B127]).

Overall, these observations confirm that the detrimental effect of IFN-I on immunocytes is evident during chronic HIV-1 infection. Despite the effective suppression of HIV viral load achieved by cART, it cannot completely reverse the immune hyperactivation and negative function induced by IFN-I. How to take advantage of IFN-I to restrict HIV-1 replication while restore the normal function of immunocytes is a key point we must balance.

Therapeutic Strategies Targeting IFN-I System *In Vivo* {#S4}
=======================================================

As is mentioned earlier, although it is apparent for the importance of IFN-I on limiting HIV-1 in the acute phase of infection, dysfunctional IFN-I is more likely to disturb the balance of immune system and be detrimental to the function of pDCs, NK cells, CD4^+^ T cells and Treg in the chronic phase. Considering the complexity of IFN-I system, manipulating this system may have unpredictable consequences *in vivo*. Thus, it is reasonable to use or block this system in the treatment and prevention of HIV infection, but the virological and immunological effects must weigh against the possible adverse events. Nowadays, therapeutic strategies toward IFN-I system consists of two aspects: administration of IFN-I or inhibiting its signaling pathway. Next, we will summarize the related studies about IFN-I system in clinical trials or in HIV-1/SIV/LCMV models.

Clinical Effects of Administration of IFN-I in HIV-1 Infection {#S4-1}
--------------------------------------------------------------

The administration of IFN-I to resist HIV infection undergoes two stages. In the era of pre-cART, IFN-I can be used as a monotherapy on HIV/AIDS. In 1990, a randomized, double-blind clinical trial conducted in 34 HIV-infected patients with the treatment of IFN-α 2b showed that early administration of IFN-I could decrease the frequency of viral isolation and slow the progress of disease despite a few side-effects such as flu-like symptoms and granulocytopenia ([@B128]). Another trial fixed attention on patients with AIDS-associated Kaposi's sarcoma. Although the absolute CD4^+^ T cells count in these patients was relatively low, 50% of them were observed on tumor regression and reduction in HIV after treatment with IFN-α for 12 weeks ([@B129]).

However, with the development of cART, IFN-I is more likely to act as an adjunct therapy instead of monotherapy. In recent 10 years, most of trials were designed to treat patients with IFN-α in association with cART, but the results varied greatly (summarized in Table [1](#T1){ref-type="table"}). In 2009, more than 200 treatment failure patients were enrolled to receive the administration of IFN-α before optimization of their antiretroviral therapy, finally they were observed a significant decrease in HIV-RNA, but no effect on CD4^+^ T cells count compared with placebo-controlled group ([@B130]). Subsequently, several studies carried out in treatment naïve patients, although the majority of these patients had a high level of HIV-RNA at first, administration of IFN-α resulted in a great decline in viral load as well as a transient increase in CD4^+^ T cells count ([@B131], [@B132]). At the same time, IFN-α was added to current treatment of cART, but the results seemed paradoxical: one indicated that IFN-α had a negative effect on disease progression ([@B133]), while the other suggested IFN-α decreased HIV reservoirs and delayed virus rebound after treatment interruption ([@B134]). Recently, two researches recruited patients who was coinfected with HIV/HCV and received IFN-α in combination with ribavirin, the result of which showed a reduction in integrated HIV-DNA and 2-LTR circular HIV-DNA ([@B135]--[@B137]). Altogether, administration of exogenous IFN-α intends to decrease HIV-RNA or HIV-DNA transiently in these studies. But the mechanism of IFN-α-induced reduction of HIV-RNA or HIV-DNA remains uncertain. Notably, it is well recognized that IFN-α treatment is related to decreasing CD4^+^ T-cell counts, raising the possibility that reductions of HIV viral load during IFN-α therapy may result from its unspecific lymphocellular toxicity ([@B138]). Although IFN-α could decrease the viral burden, adding IFN-α to the current antiretroviral therapy is not likely to enhance T cells reconstitution and improve clinical outcome. Due to the high variability of HIV, the effects of exogenous IFN-α will be rapidly compromised and dysfunctional. Indeed, these IFN-α further disturbs the balance of immune system and even have a negative effect to some extent.

###### 

Studies of IFN-I administration in human.

  Participants                                                                                                                     Intervention                                                                                                                                                                                                                                                                           Conclusions                                                                                                                                                                                     Reference
  -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  261 HIV-infected patients failing current cART treatment with plasma HIV-1-RNA \>2,000 copies/mL                                 0.5, 1.0, 1.5, and 3.0 µg/kg pegylated IFN-α or placebo with current cART × 4 weeks followed with optimized cART × 24 weeks                                                                                                                                                            IFN-α greatly decreases HIV-RNA levelNo significant changes in CD4^+^ and CD8^+^ T cells count between treatment and control arms                                                               Angel et al. ([@B130])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  174 HIV-infected patients without receiving cART with CD4^+^ T cells count ≥500 cells/μL                                         200 mg/4 h AZT × 52 weeks1 MIU/day IFN-α 2b with IFN-dose escalation × 52 weeks200 mg/4 h AZT in combination with 1 MIU/day IFN-α 2b × 52 weeks                                                                                                                                        In combination with IFN-α greater decreases HIV-RNA level than AZT aloneIFN-α transiently increase the CD4^+^ T cells count                                                                     Tavel et al. ([@B131])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  13 HIV-infected patients without receiving cART with CD4^+^ T cells count ≥300 cells/μL and plasma HIV-1-RNA \>5,000 copies/mL   180 μg/week of pegylated IFN-α 2a × 12 weeks                                                                                                                                                                                                                                           Pegylated IFN-α 2a slightly decreases HIV-RNA and increases in CD4^+^ T cells count                                                                                                             Asmuth et al. ([@B132])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  168 HIV-infected patients receiving cART with CD4^+^ T cells count ≥350 cells/μL and plasma HIV-1-RNA \<400 copies/mL            1.5 μg/kg/week pegylated IFN-α 2a from day 15 followed by cART interruption to day 8 after each cART resumption                                                                                                                                                                        IFN-α greatly decrease the CD4^+^ T cells count and do not prolong the time to treatment resumption                                                                                             Boué et al. ([@B134])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  89 HIV-infected patients without receiving cART                                                                                  1 μg/kg/week pegylated IFN-α 2a × 14 weeks + cART1 μg/kg/week pegylated IFN-α 2a × 14 weeks + cART × 36 weeks followed by interruption at week 36, 48, and 601 μg/kg/week pegylated IFN-α 2a × 14 weeks + cART × 36 weeks followed by interruption at week 36, 48, and 60 with IFN-α   Viral rebound and HIV-DNA is lower in IFN-α group but no difference after 6-month interruptionCD4^+^ T cells count is higher in IFN-α group but also no difference after 6-month interruption   Goujard et al. ([@B133])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  23 HIV-infected patients receiving cART with CD4^+^ T cells count \>450 cells/μL                                                 180 μg/week of pegylated IFN-α 2a with cART × 5 weeks + pegylated IFN-α 2a with cART interruption × 12 weeks90 μg/week of pegylated IFN-α 2a with cART × 5 weeks + pegylated IFN-α 2a with cART interruption × 12 weeks                                                                Pegylated IFN-α 2a results in a sustained control of viral replication in 45% of subjects with cART interruption and a significant reduction of integrated HIV-DNA in CD4^+^ T cells            Azzoni et al. ([@B135])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  12 HIV/HCV-coinfected patients receiving cART with suppressed HIV-1 viremia                                                      180 μg/week of pegylated IFN-α 2a and ribavirin 500--600 mg twice daily                                                                                                                                                                                                                Approximately twofold decreases of total and integrated HIV-DNA in CD4^+^ T cells during and after IFN-α/ribavirin therapy                                                                      Sun et al. ([@B138])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  15 HIV/HCV-coinfected patients17 HIV-infected patients                                                                           180 μg/week IFN-α and ribavirin 900 mg twice daily × 48 weeks + cARTcART                                                                                                                                                                                                               IFN-α obviously decreases CD4^+^ T cells count and HIV-DNA, especially 2-LTR circular HIV-DNA                                                                                                   Jiao et al. ([@B136])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  162 HCV treatment naïve or experienced patients coinfected with HIV-1                                                            ca. 750 mg/8 h telaprevir + 180 μg/week IFN-α and ribavirin 800 mg/day × 18 weeks + cART                                                                                                                                                                                               Telaprevir and IFN-α decreases CD4^+^ T cells count and three patients had a viral load increase ≥200 copies/mL                                                                                 Montes et al. ([@B137])

*IFN, interferon; IFN-I, type-I interferons; HIV-1, human immunodeficiency virus 1; cART, combined antiretroviral therapy*.

Influences of Inhibiting IFN-I Signaling *In Vivo* {#S4-2}
--------------------------------------------------

Faced with challenge about immune disorder in long-term treatment of cART, more attention is fixed on inhibiting IFN-I signaling pathway to reverse hyperactivation and exhaustion of immune system caused by redundant production of IFN-I. Recent studies *in vivo* about manipulating IFN-I system consists of two aspects: inhibiting TLR to decrease the production of IFN-I and blocking IFNAR to interfere with its signaling (summarized in Table [2](#T2){ref-type="table"}).

###### 

Studies of TLR and IFNAR blockade *in vivo*.

  Species           Virus   Methods                                                                                                                                                                 Conclusions                                                                                                                                                                Reference
  ----------------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  Human             HIV-1   13 patients without receiving cART with CD4^+^ T ≥250 cells/μL treated with chloroquine or placebo for 2 months in chronic HIV-1 infection                              Significantly reducing CD4^+^ and CD8^+^ T cells activation                                                                                                                Murray et al. ([@B140])
                                                                                                                                                                                                                                                                                                                                                                               
  Human             HIV-1   83 patients without receiving cART with CD4^+^ T ≥400 cells/μL treated with hydroxychloroquine or placebo for 48 weeks in chronic HIV-1 infection                       Hydroxychloroquine tolerated wellNo effect on CD8^+^ T cells activationIncreasing viral load and declining CD4^+^ T cells count                                            Paton et al. ([@B141])
                                                                                                                                                                                                                                                                                                                                                                               
  Human             HIV-1   19 patients on cART with CD4^+^ T ≤350 cells/μL and undetectable viral load treated with chloroquine in combination with cART for 24 weeks in chronic HIV-1 infection   Chloroquine tolerated wellIncreasing the level of IFN-α2 productionNo effect on CD4^+^ and CD8^+^ T cells recovery, T cell activation and inflammation markers in plasma   Routy et al. ([@B142])
                                                                                                                                                                                                                                                                                                                                                                               
  Rhesus macaques   SIV     Chloroquine to inhibit TLR7 and TLR9 signaling in acute in acute SIV infection                                                                                          No changing in the level of cell activationTemporary increasing the expression of interferon-stimulating genesDecreasing CD4^+^ T cells recovery                           Vaccari et al. ([@B143])
                                                                                                                                                                                                                                                                                                                                                                               
  Rhesus macaques   SIV     IFNAR antagonist to block IFN-α2 activity or exogenous IFN-α treatment in acute SIV infection                                                                           Higher viral load and accelerating disease progression whether by administration of IFNAR antagonist or induction of an IFN-tolerate state                                 Sandler et al. ([@B17])
                                                                                                                                                                                                                                                                                                                                                                               
  Mice              LCMV    Anti-IFNAR (MAR1-5A3) and clodronate liposomes in chronic LCMV infection                                                                                                Preserving the function of virus-specific B cells and accelerating neutralizing antibody production                                                                        Moseman et al. ([@B145])
                                                                                                                                                                                                                                                                                                                                                                               
  Hu-mice           HIV-1   Using a monoclonal antibody to block IFNAR2 (clone MMHAR-2) in chronic HIV-1 infection                                                                                  Reversing immune exhaustionIFNAR blockade in combination with cART achieving faster viral suppression and lower HIV-1 reservoirs                                           Zhen et al. ([@B144])
                                                                                                                                                                                                                                                                                                                                                                               
  Hu-mice           HIV-1   Using a monoclonal antibody to block IFNAR1 (extracellular domain and transmembrane domain) in chronic HIV-1 infection                                                  Greatly suppressing aberrant immune activationReducing the exhaustion of T cellsDecreasing HIV-1 reservoirs and delaying virus rebound after cART discontinuation          Cheng et al. ([@B103])

*HIV-1, human immunodeficiency virus 1; IFNAR, IFN-α/β receptor; TLR, toll-like receptor; cART, combined antiretroviral therapy; SIV, simian immunodeficiency virus; LCMV, lymphocytic choriomeningitis virus*.

As is mentioned earlier, pDCs play a significant role in producing IFN-I. It may be an effective way to administrate chloroquine, a novel endosomal inhibitor in blocking TLR7 and TLR9 in pDCs, to reduce IFN-I products ([@B139]). Unfortunately, the results of several clinical trials about this strategy seem complicated. First, after receiving chloroquine for 2 months in 13 cART-naïve patients, decreased CD4^+^ and CD8^+^ T cells activation were observed ([@B140]). Although the result was encouraging, later research indicated that receiving hydroxychloroquine seemed to be no effect on CD8^+^ T cells activation while hindered the recovery of CD4^+^ T cells ([@B141]). Similarly, chloroquine had a negative influence on immunological non-responders ([@B142]). Therefore, the impact of reducing IFN-I production through chloroquine is still controversial, which needs further research.

On the other hand, antagonist of IFNAR has been used to specifically block IFN-I signaling in recent years. In 2014, a study showed that IFNAR blockade in the acute SIV infection resulted in increasing viral load, down-expression of antiviral genes and leading to the depletion of CD4^+^ T cells ([@B17]). Two studies conducted in the model of hu-mice also found that IFNAR blockade was an effective way to diminish T cells exhaustion and restore immune function in the chronic HIV-1 infection. More importantly, declined in HIV-1 reservoirs was also observed in these researches ([@B103], [@B143], [@B144]). However, in the model of LCMV, blocking IFNAR can completely reverse the depletion of LCMV-specific B cells and promote the secretion of neutralizing antibody to resist infection ([@B145]). These data suggest that IFNAR blockade in combination with cART may provide a potential therapeutic strategy for HIV-1 infection. On account of the complex impact of blocking IFNAR *in vivo*, the assessment of anti-immunological consequences and side-effects must be carried out before widespread implementation.

Conclusion {#S5}
==========

Innate immune system provides an immediate defense against pathogens to protect our body from infection by other organisms. As the most important effector molecule, IFN-I is powerful to suppress HIV and stimulate the expression of a bunch of antiviral genes replication at the early phase of infection. Although IFN response seems to be effective, HIV evades the IFN-mediated antiviral activities later since the stimulation of resistance factors. According to the results of clinical trials mentioned earlier, administration of IFN-I may have no benefit on clinical outcome, confirming that it fails to restrict and clear HIV *in vivo*. However, several aspects about this process still require further investigation: in addition to IFN-α and IFN-β, the role of the other subtypes of IFN-I in this process has not been clear; the separate pathways to recognize HIV nucleic acid (ssRNA, dsRNA, or cDNA) needs to be identified in all types of infected cells; and the exact mechanism of HIV escape also have to be clarified. Future studies should address these uncertain questions.

Even if IFN-I do function in the early HIV infection, continuously production promotes immune activation and ultimately exhaustion of immune system in the chronic phase. The detrimental effects of IFN-I on different lymphocyte have been intensely reported. But the regulatory mechanism in different lymphocytes has to be figured out.

Although the long-term clinical results of the administration of exogenous IFN-α seem to be invalid in the acute phase of HIV-1 infection with or without cART, it has been identified that this treatment could reduce the viral load transiently. Future studies should lay emphasis on whether supplementation of IFN-I to cART therapy during chronic infection could further decrease the HIV-1 reservoirs.

Moreover, in animal infectious model, IFN-I blockade strategy contributing to the recovery of T cells and decline in HIV reservoirs have been observed, suggesting that animals obtain benefits from this strategy. Although the results are encouraging, this approach has not been tried in human for its complicate effects. Further proof needs to be provided whether it is effective to decrease the morbidity of AIDS and reduce reservoirs through blocking IFN-I signaling, as this strategy may decrease immune activation whereas increase T cell responses. What is more, if it is possible, clinical trials about effective monoclonal antibody toward IFN-I blockade are expected to conduct in human.

In summary, despite long terms of research, the exact relationship between the production of IFN-I, the pathway of viral evasion, and the induction of pathogenic cellular immunological injury has not been clearly deciphered. Numerous questions remain to answer. A better understanding of the role of IFN-I in HIV pathogenesis will aid in managing this pathway for therapeutic purposes.
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